FDA Rejects Corcept’s Relacorilant for Cushing Syndrome-Related Hypertension

What happened

The US FDA declined to approve Corcept Therapeutics’ relacorilant for hypertension in patients with hypercortisolism (Cushing syndrome), citing insufficient evidence of effectiveness and an unclear benefit-risk profile. Corcept said it plans to meet with the FDA on next steps, and shares fell sharply on the news.

Why it matters for markets

A “complete response” like this can reset timelines by years, force new trials, and pressure funding for small/mid-cap biotechs. At the same time, it can shift share toward already-approved alternatives and benefit clinical trial infrastructure providers.

WINNERS

Approved Cushing syndrome treatment alternatives (share shift when new entrant is delayed)

 ...